PORTFOLIO

Alder focuses on building a novel cell therapy platform with best functional cells based on the most simple and robust processes. The unique platform will allow better pluripotent cell therapy treatment for the wider masses and being part of opening a new era in medicinal treatment.

Clinical stage biopharmaceutical company developing novel drugs to treat heart failure, increasing contractility. The lead program AC01 is planned to enter phase 2 clinical development in 2022.

Inspired by physiological processes, Vitara is developing a fluid-filled incubator for premature infants to continue to develop critical organ functions and reduce mortality and morbidity compared to current standard of care.

Xintela is a publicly listed biopharma company developing stem cell-based treatments focusing on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancer.

A3P's lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with a proprietary algorithm in order to detect aggressive prostate cancer at an early stage.

Swedish biotechnology company with a long history of developing and manufacturing hyaluronic acid raw material and products in three different areas: Ophthalmology, Aesthetics and Orthopaedics. They are based in Strömstad with a manufacturing facility in Portugal.

XNK is a clinical stage immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. Their autologous lead drug candidate, CellProtect, is being investigated in a phase II study in multiple myeloma.

Geneos Therapeutics is a US-based clinical stage biotherapeutics company within the immunotherapy space. The GT-EPIC™ platform allows Geneos to develop exquisitely personalized DNA vaccines tailored to each patient's unique tumour mutations.

Microbiotica is a Cambridge-based microbiome company that identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets, initially focussing on immuno-oncology and ulcerative colitis.

Strike Pharma are developing a novel next generation Antibody-Drug Conjugate (ADC) technology within the immuno-oncology precision medicine space, the ADAC technology. ADACs are short for Adaptable Drug Affinity Conjugates and are built to improve the delivery of tailor-made synthetic molecules to specific cell types for improved immune modulation.

Synerkine Pharma is a Dutch biopharmaceutical company developing a novel class of biologics, called Synerkines, that connect different cytokines and enhance their activity via a unique mode of action. Their initial focus is on osteoarthritis, chronic pain and chemotherapy-induced peripheral neuropathy.

Lipum is a preclinical drug development company developing a biological anti-inflammatory drug candidate with a novel mechanism of action, targeting the BSSL protein. Their initial focus is on the treatment of rheumatoid arthritis and juvenile idiopathic arthritis.

NorthX Biologics is a Swedish pharmaceutical company with a focus on process development and large-scale production of advanced biological drugs. The Swedish Government has given Vinnova (Sweden's innovation agency) the mandate to support the establishment of an innovation hub alongside NorthX Biologics in Matfors.

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development. It uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer.

Eurocine Vaccines is a preclinical vaccines company with a portfolio strategy. Their lead vaccine candidate is against chlamydia, for which they have also developed a diagnostic test.

Toleranzia aims to restore the immune system's normal ability to tolerate the endogenous substances that are mistakenly targeted in the development of severe autoimmune diseases. The company's most advanced drug candidate, TOL2, is being developed to cure myasthenia gravis.

EpiEndo is a clinical stage pharmaceutical company developing a proprietary portfolio of drugs to address the huge global burden of chronic respiratory diseases. Their lead compound is a non-antibiotic analogue of azithromycin which modulates inflammation through strengthening the lung epithelium.

Empros is a late phase clinical stage company developing EMP16, an anti-obesity drug product. The product is a re-purposing of established APIs. Core competences are reformulation and obesity related endocrinology.

Prokarium is a clinical stage venture developing microbial immunotherapies, leading with a therapeutic for Bladder Cancer and a vaccine for Enteric Fever, the latter in partnership with Wellcome.

Symcel is a medtech company developing an analytical instrument for direct metabolic measurements. In commercial phase on R&D markets with early traction and KOL support, in development of precision diagnostics for infectious diseases.

Nanologica develops nanoporous silica particles for two application areas: For drug development it provides a drug delivery platform for inhaled formulations. For chromatography the company's silica media can reduce the production cost for insulin manufacturers.

KAHR is a clinical stage cancer immunotherapy company developing novel bi-functional fusion proteins. KAHR's lead product, DSP107, is a first-in-class CD47x41BB targeting agent currently in clinical development for patients with solid tumors.

Atrogi is a preclinical company developing a first-in-class drug for the oral treatment of type 2 diabetes. The unique MoA circumvents the insulin-signaling pathway, which is malfuntioning in type 2 diabetic patients.

Amarna Therapeutics is a preclinical gene therapy company, about to enter clinical stage. The Company's new platform solves a fundamental problem and known limiting factor of existing platforms

Sixera is developing a NCE, SXR1096 for the treatment of a ultra-orphan skin disease called Netherton syndrome. SXR1096 is a small molecule formulated in a cream to be applied topically on the skin.

Provell Pharmaceuticals specializes in the marketing of world class pharmaceutical products in the United States. It seeks to provide innovative products with unique or enhanced delivery systems for better quality, stability or patient adherence at a lower cost.

Chromafora is a deep-tech chemical water treatment company. It has patented methods for treating waste streams to separate heavy metals and enable recycling and to remove PFAS or other organic contaminants from water.

Buzzard conducts clinical development of a potent Interleukin-1 inhibitor called Isunakinra in the US for the treatment of solid tumors in combination with a PD-1 inhibitor (Checkpoint Inhibition). Isunakinra is currently in phase I/II.

Beactica is a discovery-stage company developing first-in-class small molecule modulators to become next-generation breakthrough therapies for life-threatening conditions, with a focus on oncology. Beactica is headquarted in Uppsala, Sweden.

Vironova is providing comprehensive hardware, software and services for the analysis of nanoparticles. Vironova turns images into evidence and decision support in development of viral vectors for gene therapy

Dedicated orphan drug development company with two late-stage orphan drug assets: Emcitate® for treatment of MCT8 deficiency and and Aladote® for prevention of acute liver injury caused by paracetamol poisoning. Listed on the Nasdaq Stockholm main market.